Clinical Trial Update: Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial of thalidomide for chronic graft-versus-host disease after bone marrow transplant has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific | Phase 2 | Status: COMPLETED